ArticlePloS one2025
Clinical outcome of radiofrequency ablation in patients with hepatocellular carcinoma aged 80 years and older.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical-pathological characteristics and prognosis of elderly primary liver cancer patients.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimThe incidence of hepatocellular carcinoma (HCC) is positively correlated with age, and the population of patients with HCC was also older at the time of clinical diagnosis. In the SURF trial, elderly people aged ≥80 years were excluded. We aimed to study the efficacy and safety of radiofrequency ablation (RFA) for patients aged over 80 years.
methodsPatients who underwent RFA at our institution for the initial treatment of HCC tumors with largest diameters of ≤3 cm, and ≤3 HCC nodules from January 2011 to December 2023. Treatment outcomes and prognoses were examined in the elderly group (≥80 years) and in the nonelderly group (<80 years). The Cox proportional hazards model was used to determine the factors associated with treatment outcomes and prognoses.
resultsOf the 518 eligible patients, 136 patients were aged ≥80 years. The median overall survival (OS) values were 80 (95%CI; 60-96) and 123 (95%CI; 101-nucleotide analogs (NA)) months (p = 0.021) in the elderly and nonelderly groups, respectively. For liver disease-related deaths, the median OS values were 97 (95% CI; 80-NA) and NR (95% CI; NA-NA) months (p = 0.62) in the elderly and nonelderly groups, respectively. In the multivariate analysis, factors associated with OS were ALBI grade 2 or 3 (HR, 1.67, 95%CI; 1.07-2.60), DCP ≥ 40 mAU/ml (HR, 2.08, 95%CI; 1.42-3.04), persistent hepatitis C virus (HCV) infection (HR, 5.46, 95%CI; 3.08-9.69), and nonviral liver disease (HR, 4.19, 95%CI; 2.32-7.57). The median recurrence-free survival values were 16 (95%CI; 14-22) and 26 (95%CI; 19-30) months, respectively (p = 0.023). HCC recurrence was significantly associated with the male sex (HR, 1.50, 95%CI; 1.17-1.93), elderly group (HR, 1.37, 95%CI; 1.10-1.95), ALBI grade 2 or 3 (HR, 1.39, 95%CI; 1.07-1.80), DCP ≥ 40 mAU/ml (HR, 1.41, 95%CI; 1.10-1.81), and persistent HCV infection (HR, 1.67, 95%CI; 1.30-2.15). The factors associated with liver disease-related death were ALBI grade 2 or 3 (HR, 2.17, 95% CI; 1.26-3.75), DCP ≥ 40 mAU/ml (HR, 2.33, 95% CI; 1.47-3.69), and persistent HCV infection (HR, 2.22, 95% CI; 1.39-3.56).
conclusionsIn RFA for tumors with diameters of ≤3 cm and ≤3 HCC nodules, age over ≥80 years was not a significant factor associated with OS or liver disease-related death. The results support that RFA would be a promising treatment option for patients with HCC patients aged ≥80 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.